MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2459/jcm.0000000000001800

Медицинская библиотека · Journal of cardiovascular medicine (Hagerstown, Md.) · 2025

Neurohormonal therapies at baseline and follow-up and survival in wild-type transthyretin cardiac amyloidosis.

Aimo Alberto, Milani Paolo, Tini Giacomo, Vergaro Giuseppe, Basset Marco, Musumeci Beatrice, Zampieri Mattia, Ruotolo Irene, Fabris Francesca, Foli Andrea, Argirò Alessia, Mazzoni Carlotta, Schiavo Maria Alessandra, Longhi Simone, Saturi Giulia, De Fazio Ludovica, Varrà Guerino Giuseppe, Serenelli Matteo, Fabbri Gioele, De Michieli Laura, Palmiero Giuseppe, Ciliberti Giuseppe, Carigi Samuela, Zanoletti Margherita, Mandoli Giulia Elena, Ricci Lucchi Giulia, Panichella Giorgia, Rella Valeria, Monti Enrico, Gardini Elisa, Bartolotti Michela, Crotti Lia, Merli Elisa, Mussinelli Roberta, Vianello Pier Filippo, Cameli Matteo, Marzo Francesca, Guerra Federico, Limongelli Giuseppe, Cipriani Alberto, Perlini Stefano, Obici Laura, Perfetto Federico, Barbato Emanuele, Porto Italo, Sinagra Gianfranco, Merlo Marco, Biagini Elena, Cappelli Francesco, Palladini Giovanni, Emdin Michele, Canepa Marco

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Transthyretin cardiac amyloidosis (ATTR-CA) typically manifests with heart failure. Discontinuing beta-blockers and avoiding angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARB) in patients with ATTR-CA has been recommended.

METHODS

We investigated the prescription of neurohormonal therapies and their relationship with all-cause mortality in a multicenter cohort.

RESULTS

Patients (n = 926) had a median age of 79 years (interquartile range 74-83), 90% were men, 17% had a left ventricular ejection fraction (LVEF) 40% or less, and 27% were in New York Heart Association (NYHA) class III/IV. At diagnosis, 60% of patients were on beta-blockers, 58% on ACEi/ARB/ARNI, and 35% on MRA. Patients on beta-blockers had more often NYHA class III/IV, a greater burden of comorbidities, and lower LVEF, and those on ACEi/ARB/ARNI had more comorbidities. Nonetheless, the survival of patients on beta-blockers or ACEi/ARB/ARNI was not significantly shorter over a 2.5-year follow-up (1.6-3.8) (P = 0.577 and P = 0.977, respectively), and patients on both drugs did not have a worse outcome than those not receiving any neurohormonal drug (P = 0.575). During the entire follow-up, the number of neurohormonal drugs remained unchanged in 54%, decreased in 27%, and increased in 19%. Patients with a number of neurohormonal drugs either unchanged or increased had a lower risk of mortality (odds ratio 0.71, 95% confidence interval 0.53-0.95, P = 0.023).

CONCLUSION

ATTRwt-CA patients on beta-blockers or ACEi/ARB/ARNI at diagnosis did not have a shorter survival. Beta-blockers were discontinued less often than were ACEi/ARB/ARNI. There was no sign of better outcomes in patients discontinuing these therapies, or worse outcomes in those starting them.

Для цитирования: Aimo Alberto, Milani Paolo, Tini Giacomo, Vergaro Giuseppe, Basset Marco, Musumeci Beatrice, Zampieri Mattia, Ruotolo Irene, Fabris Francesca, Foli Andrea, Argirò Alessia, Mazzoni Carlotta, Schiavo Maria Alessandra, Longhi Simone, Saturi Giulia, De Fazio Ludovica, Varrà Guerino Giuseppe, Serenelli Matteo, Fabbri Gioele, De Michieli Laura, Palmiero Giuseppe, Ciliberti Giuseppe, Carigi Samuela, Zanoletti Margherita, Mandoli Giulia Elena, Ricci Lucchi Giulia, Panichella Giorgia, Rella Valeria, Monti Enrico, Gardini Elisa, Bartolotti Michela, Crotti Lia, Merli Elisa, Mussinelli Roberta, Vianello Pier Filippo, Cameli Matteo, Marzo Francesca, Guerra Federico, Limongelli Giuseppe, Cipriani Alberto, Perlini Stefano, Obici Laura, Perfetto Federico, Barbato Emanuele, Porto Italo, Sinagra Gianfranco, Merlo Marco, Biagini Elena, Cappelli Francesco, Palladini Giovanni, Emdin Michele, Canepa Marco. Neurohormonal therapies at baseline and follow-up and survival in wild-type transthyretin cardiac amyloidosis.. Journal of cardiovascular medicine (Hagerstown, Md.). 2025. DOI: 10.2459/jcm.0000000000001800.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.